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The thyroid cancer is a rare oncological entity, representing no more than 1% of all human malignant neoplasms. Recently, it
has been demonstrated a sharp increase in incidence of differentiated thyroid carcinoma, equally occurring in both sexes. So far,
multiple genetic alterations have been identified in differentiated thyroid carcinoma, leading to investigate the clinical utility of
genetic studies. In particular, molecular genetic approaches searching for gene mutations in the material collected by fine needle
ago-biopsy may have a particular utility in small nodules and in those specimens with an indeterminate cytology. The expansion of
knowledge about genetic mutations occurring in different thyroid tumors has characterized recent years, allowing the identification
of a correlation between specific mutations and phenotypic characteristics of thyroid cancers, essential for their prognosis. This
review will briefly report on the histological features and the new entity represented by thyroid microcarcinoma and will focus on
both environmental and genetic aspects associated with the occurrence of thyroid cancer.
1. Introduction
The thyroid cancer (TC) is a rare oncological entity,
representing no more than 1% of all human malignant
neoplasms. However, it represents the most common malig-
nant endocrine neoplasia whose incidence has progressively
increased over the past two decades, according to the
majority of Tumors Registries. In fact, the data collected
at the Surveillance Epidemiology and End-Results Cancer
Registries program (SEER) [1] indicate an annual average
prevalence of thyroid carcinoma (TCa) of 6.6/100.000 (9.5
and 3.5/100.000 for women and men, resp.) with an annual
increase >5% in the period 1975–2002.
In a very recent study in the United States (U.S.), a
sharp increase in incidence of differentiated TC, equally
occurring in both sexes and independently by the sizes of
the lesions, has been reported. However, the detection at
a preclinical stage, through neck ultrasounds (US), of a
greater number of asymptomatic TCas and the progressive
increase in both the prevalence and incidence of nodular
thyroid disease cannot represent the only explanation for
these increased incidence rates. Such findings are mainly due
to an improved diagnostic histopathology with particular
regard to the cytological diagnosis on fine needle ago-biopsy
(FNAB). Consequently, other factors such as environmental
influences and molecular alterations must be taken into
account [2].
This review will briefly report on histological features
and the new entity represented by thyroid microcarcinoma
(TmCa) and will focus on both environmental and genetic
aspects associated with the occurrence of TC.
2. Histological Features
TCs are divided into papillary carcinoma (PTC) (MIM
#188550), follicular carcinoma (FTC) (MIM #188470),
medullary thyroid carcinoma (MTC) (MIM #155240),
anaplastic thyroid carcinoma (ATC), primary lymphoma of
the thyroid (PLT), and primary sarcoma of the thyroid (PST).
The PTC accounts for 80% of all thyroid malignancies
[3] whereas FTC, the second most common malignancy
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Figure 1: Frequency of thyroid neoplasms.
Table 1: Correlation between incidence and histological type of
TCs.
Histotype Incidence
PTC (i) Childhood
(ii) <50 years
FTC (iii) <60 years
ATC (iv) 60–70 years
of TC, represents approximately 15% of cases [4]. The
MTC represents 3% of thyroid malignancies [4]. ATC,
approximately representing 2%, is the most aggressive form
of TC, while PLT and PST are very rare (Figure 1).
Through a careful revision of several published studies,
a correlation between age of incidence and histological
type can be established. In fact, PTC is more frequent in
childhood and <50 years [5], FTC in patients <60 years [6],
and the ATC 60–70 years [7] (Table 1).
3. Thyroid Microcarcinoma (TmCa):
A “New Entity”
TmCa, diameter <1 cm, is an increasing pathological finding
that could be regarded as a thyroid incidentaloma. In fact,
as it happens for adrenal gland incidentaloma, TmCa is
occasionally identified at US of the neck performed for other
reasons. Most of TmCas are PTC with a sclerotic appearance
of the nodule and similar prevalence in both sexes. TmCa
is rare in children; whereas in autoptic series of adults,
their frequency is similar in all of the age groups, indicating
that in the absence of screening techniques enabling their
identification TmCas occur in young adults and most cases
regress or do not ever reach the clinical expression [8].
4. Mortality
Despite the significant increase in its incidence, mortality
for TC has not increased in equal measure. It appears two
times higher in female subjects with a rate of the annual
mortality between 0.4–2.8 and 0.2–1.2/100.000, respectively,
for women and men [1].
5. Risk Factors
The multifactor etiology of TC is the result of complex
genetic and environmental factors interaction in individuals
at risk. Epidemiological studies suggest the following main
risk factors.
6. Gender and Age
TC is 2–4 times more frequent in women who generally
exhibit a better prognosis than men in whom a higher
malignant progression of nodules has been reported. It is rare
in patients aged <16 years, presenting an annual incidence of
0.02–0.3/100.000, and extremely uncommon below the age
of 10 years [9–11]. Its incidence increases with ageing and
the average age at diagnosis is 45–50 years. However, the
following issues have to be stressed: (1) although rare, the
presence of TC in childhood accounts for a more advanced
disease at diagnosis; and (2) in patients aged >60 years an
increased risk for malignancy of thyroid nodules has been
observed.
7. Ethnic Differences
A geographic and ethnic variability of TC incidence has been
reported. In areas such as Iceland, Hawaii, the Philippines,
Japan, and Israel its incidence is higher than in North
America, Canada, and U.S.
In U.S., the TCa is more frequent in Caucasian descent
subjects than Afro-American, Hispanic, Hawaiian, Chinese,
or Japanese women, whose incidence is still twice as high in
their countries of origin. All these findings suggest that such
differences may be attributable to both environmental (e.g.,
dietary habits) and genetic factors [9, 12].
8. Environmental Factors
In this section we will consider the role of several parameters
such as the (1) exposure to ionizing radiations, (2) age at the
time of the exposure, (3) presence of a previous history of
benign thyroid disease, (4) role of the dietary iodine intake,
(5) role of the body mass index, and (6) role of hormonal
factors.
8.1. Previous Exposure to Ionizing Radiation. The role of
a previous exposure to ionizing radiation in thyroid car-
cinogenesis has been established since 1950 following the
explosion of the atomic bomb in Japan.
Previous exposure to ionizing radiation for external
irradiation of the neck increases the incidence of thyroid
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nodules, either benign or malignant, and palpable nodules
are detected in 20%–30% of people exposed to radiation
[13], as well it happens in pediatric patients undergoing
radiation therapy for oncological and haematological malig-
nancies such as lymphoma or leukemia [14, 15].
The minimum latency period between exposure and
clinical evidence of thyroid disease has been reported to
be at least 4-5 years, reaching the maximum peak 20 years
from exposure to decrease thereafter. The risk increases from
medium doses above 10 cGy, and for doses up to 1500 cGy
a linear dose-cancer risk can be observed. For higher doses
the risk decreases probably in relation to radio-induced cell
necrosis.
8.2. Age at the Time of Irradiation. It represents the main risk
factor and after 15–20 years there is no longer an increased
risk. In children exposed to doses of 1 Gy, the excess risk for
TCa is equal to 7.7 [16].
Several studies conducted after the Chernobyl nuclear
disaster have shown an increased incidence of TCs in subjects
that at that time were aged between 5 months and 10
years [17, 18]. The average age at diagnosis of TCa was 14
years with no substantial gender-related difference in the
incidence.
According to the pathology findings, the most frequent
histological features were represented by solid and follicular
variants of PTC. At the time of diagnosis, the disease was in
an advanced stage, already exhibiting lymph node and lung
metastases, a more aggressive biological behaviour, and it
resulted to be more frequently associated with autoimmune
thyroiditis [17, 18].
8.3. Previous History of Benign Thyroid Disease. In subjects
suffering from benign thyroid nodules and, to a lesser per-
centage, in subjects suffering from goiter, a higher frequency
of TC has been demonstrated [19, 20]. Such a correlation
suggests either the presence of common environmental
causal factors or the lack of difference in the rate of
malignancy of single or multiple nodules, not yet confirmed.
Several studies reported an increased incidence of malig-
nant nodules (from 0.4% to 9.8%) in individuals with
Basedow’s disease (MIM #275000) [19, 20]. These studies
also noted an increased risk for those subjects who had
palpable nodules, and also evaluated through neck US or
thyroid scintigraphy, compared with those with diffuse non-
nodular goiter. Moreover, TCs that occurred in patients with
Basedow’s disease seem to have a more aggressive clinical
behavior [21].
Although hyperthyroidism (toxic adenoma and toxic
multinodular goiter) or Hashimoto’s thyroiditis (MIM
#140300) do not represent additional risk factors for TCa,
affected subjects have a higher risk to develop a thyroid
lymphoproliferative disease such as a thyroid lymphoma
[22, 23].
8.4. Contribution of Iodine in the Food. In areas with iodine
deficiency, a higher incidence of thyroid nodules and TCs
has been observed. However, after correction for the greatest
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Figure 2: Contribution of iodine in the food to the thyroid
tumorigenesis.
number of nodules, the percentage of TCa in thyroid nodules
is similar to the one found in areas with normal intake of
dietary iodine.
Different histotypes occur in accordance to the con-
tribution of dietary iodine (Figure 2). In presence of a
sufficient iodine intake, more than 80% of cancer consist
of PTC; whereas in areas with iodine deficiency follicular
and anaplastic figures are more frequently reported (approxi-
mately 2-3 times higher than observed in areas with adequate
iodine intake) [11].
8.5. Body Mass Index. Several case-control studies have
shown an increased risk of TCa in patients with high body
mass index (BMI). The risk would be increased by 5-fold
in obese men and 2 times in obese women (>97 percentile),
compared to the risk observed in patients with weight <3rd
percentile. In women (especially in postmenopausal age) a
weight gain >14% appears to positively correlate with the
onset of TCa [24, 25].
8.6. Hormonal Factors. The male-to-female incidence ratio
has been reporting to be different according to the period
of life in which TC occurs. In women of childbearing
age, this ratio is about 2–4 : 1 and is reduced to 1.5 : 1 in
older prepuberal and menopause individuals [26, 27]. In
pregnancy, the diagnosis of goiter or thyroid nodules is
frequent and an increase in thyroid volume and nodules may
occur. Consequently, it has been hypothesized as a role for
hormonal factors or other factors related to pregnancy in the
pathogenesis of TCa [28]. However, it is still unclear why a
female predominance exists [29].
9. Genetic Factors
In order to explain the role of genetics in thyroid carcinogen-
esis, we will consider the (1) presence of a positive familial
history for TC and associated diseases and (2) molecular
genetic aspects including (a) fine mechanisms such as gene
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mutations, both at nuclear and mitochondrial level, (b) gross
mechanisms represented by gene rearrangements and loss of
heterozygosity (LOH), and (c) a brief paragraph concerning
the more recent knowledge on the role of microRNAs.
9.1. Familial History and Associated Diseases. In this para-
graph, only nonmedullary thyroid tumors will be considered.
Familial MTCs will be treated in the paragraph of RET proto-
oncogene.
In 3%–5% of patients with TC, a positive family his-
tory for thyroid tumors in first-degree relatives can be
detected. Indeed, in the setting of familial nonmedullary
TCa, (FNMTCa), PTC mainly occurs in more members of
the pedigree, being inherited as a dominant autosomal trait
with an incomplete penetrance. In the affected subjects, the
aggressiveness of the tumor is higher than that observed in
the general population (high frequency of multifocal form
and an higher rate of relapse compared to patients with
sporadic PTC), but this observation has not been confirmed
in other series [30].
Of course, genetic factors are responsible for some famil-
ial syndromes associated with high prevalence of nodular
thyroid disease and TCa, such as familial polyposis of
colon (FAP), Cowden’s disease (CD), and Carney’s complex
(CNC).
In FAP (MIM #175100), the risk of developing mul-
ticentric PTC, in particular the cribriform variant [31], is
about 100 times higher than the one observed in the general
population [32]. Female subjects below 35 years are more
frequently affected.
In CD (MIM #158350), an autosomal dominant disease
with multiple hamartomas in different tissues, the risk
of PTC, or FTC is higher than observed in the general
population [33].
CNC (MIM #160980) is a multiple endocrine neopla-
sia syndrome inherited as an autosomal dominant trait.
The disease is characterized by spotty skin pigmentation,
cardiac and extracardiac myxomatosis, schwannomas, and
endocrine tumors, like multiple hypersecretory adrenal nod-
ules, growth hormone-secreting pituitary tumors, gonadal
tumors, and thyroid neoplasms, either follicular or papillar
form. CNC is caused by loss of function mutations in
PRKAR1A gene, which encodes the type 1A regulatory
subunit of protein kinase A, a modulator of intracellular
signaling of PKA (PKA; cyclic AMP (cAMP)-dependent
protein kinase) [34–36].
Sporadic thyroid tumors can rarely accommodate muta-
tions, and in fact it is very rare that these tumors can accom-
modate somatic mutations of PRKAR1A [37, 38].
9.2. Molecular Genetic Aspects. In recent years, the molecular
bases of thyroid carcinogenesis have been thoroughly inves-
tigating. The most frequent genetic alterations, detected by
molecular biology studies over the past 20 years, are mainly
represented by the activation of oncogenes such as BRAF,
RAS, RET, and NTRK1 and the silencing of tumor suppressor
genes such as PTEN, TP53.
Table 2: Prevalence of major genetic alterations in all of the TCs
but MTC.
Genes PTC FTC ATC
BRAF 45% RARE 20%
RAS 10%–20% 40%–50% 50%–60%
NTRK1 <5% — —
PI3K/AKT and PTEN — 7% 15%
TP53 RARE RARE 60%–80%
CTNNB1 RARE RARE 66%
RET/PTC 25%–30% — —
PAX8/PPARγ — 35% —
9.2.1. Fine Mechanisms: Nuclear and Mitochondrial
Gene Mutations
Nuclear Genes
BRAF Gene. BRAF gene (OMIM #115150) encodes a protein
belonging to the family of serine-threonine kinases, activator
of mitogen-activated protein kinase (MAPK) with a high
affinity for MEK1 and MEK2, MAP kinase kinases, leading
to their phosphorylation more efficiently than other RAF
isoforms [39].
MAPKs respond to mitogenic extracellular stimuli and
regulate gene expression, mitosis, differentiation, prolifera-
tion, and cell survival/apoptosis. MEK1 and MEK2 activate
the serine/threonine specific protein kinases ERK1 and
ERK2. Activated ERKs are pleiotropic effectors of cell
physiology and play an important role in the control of gene
expression involved in the cell division cycle, apoptosis, cell
differentiation, and cell migration [40, 41].
BRAF and PTC. BRAF mutations are the most common
genetic alterations found in PTCs, being present in approx-
imately 45% of these tumors [42–44] (Table 2). BRAF
mutations are present in 40%–70% of PTCs with higher
percentage of positivity in more aggressive variants such as
“tall cell” dedifferentiated forms [45].
In particular, the genetic alteration with the higher
prevalence in classical PTCs involves the nucleotide 1799
determining a valine-glutamate substitution at amino acid
residue 600 (V600E) with consequent activation of BRAF
kinase that results in a continuous phosphorylation of MEK
and MAPK pathway effectors. Such a mutation is rare in FTC
[43, 46, 47].
Two more rare activating mutations of BRAF have been
also described in PTCs: (a) the K601E point mutation,
small in-frame insertion or deletion surrounding codon 600
and determining a lysine-glutamic substitution, and (b) the
AKAP9-BRAF rearrangement that is more common in those
PTCs associated with a previous radiation exposure [48–51].
AKAP9 (A kinase (PRKA) anchor protein (yotiao) 9) gene
encodes a member of the AKAP family, proteins which have
the common function of binding to the regulatory subunit of
protein kinase A (PKA) [52].
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Table 3: RET and MTC: Genotype-phenotype correlation.
RET receptor protein RET mutation CMT progression Level of the risk of progression
Exon 10
Cys 609
Partially slow 5–7 years
High
Cys 611
Cys 618
Cys 620
Exon 11
Cys 630
Intermediated ∼1 year
Cys 634
Transmembrane domain RETS649L
Slow 6–22 years Intermediated
Exon 13
Glu 768 Asp
Leu 790 Phe
Tyr 791 Phe
Exon 14 Val 804 Met/Le
Exon 15 Ser 891 Ala
Exon 16 Met 918 Thr Fast <1 year Very high
BRAF-PTC Genotype/Phenotype Correlation. The character-
istics of aggressiveness of PTCs, such as extrathyroidal
extension, advanced presentation, presence of lymph node,
or distant metastases have been associated in many studies
with the presence of BRAF mutation [53–57], even if it
has been proven to be an independent predictor of tumor
recurrence, also at an early stage of disease [55, 58].
The BRAF mutation is thought to account for the
impairment of the function of the sodium-iodine symporter
(NIS) and other molecular pathways involved in the iodine
metabolism of the follicular cell. In fact, BRAF mutation has
been found to be associated either with a decreased iodine
intake in some thyroid tumors or the failure of response to
therapy in disease relapse [55, 59].
BRAF and ATC. A BRAF mutation has been reported in 20%
of ATCs, exhibiting also areas of well-differentiated PTC, and
15% of poorly differentiated TCs [53, 54, 60] (Table 2).
BRAF Mutant Animal Models. The involvement of BRAF in
thyroid tumorigenesis has been also suggested by studies on
transgenic mice with thyroid-specific expression of BRAF
V600E [61].
In fact, these mice developed a PTC with invasion of
blood vessels, thyroid capsule, and perithyroid skeletal mus-
cle. They are all features of aggressiveness, demonstrating a
progression to poorly differentiated TC.
RAS Gene. HRAS, KRAS, and NRAS genes are members of
the RAS family (OMIM #109800) coding for a G-protein.
When activated, RAS protein starts the intracellular signal
transduction through the release of GTP and the activation
of MAPK and PI3K/AKT pathways (see below). Therefore,
an increase of the affinity for GTP and inactivation of the
GTPase function are explained by the presence of point
mutations in the RAS domains, especially in codons 12, 13,
and 61, which determine a constantly active RAS mutant
protein [62].
RAS and PTC. Point mutations of RAS are found in 10%–
20% of PTCs [63–65] (Table 2).
RAS and FTC/Follicular Adenomas. RAS mutations have
been also found in 40%–50% of FTCs and in 20%–
40% of follicular adenomas, the latter with a prevalent
microfollicular pattern of growth [66–70]. Often, the NRAS
and HRAS mutations occur at codon 61. They have a low
incidence in oncocytic tumor (designated as oncocytic if
at least 75% of their constituent cells can be described as
oncocytes) and, in fact, these mutations have been reported
only in 0–4% of follicular adenomas and in 15%–25% of
FTCs [68, 71, 72] (Table 2).
RAS and ATC. Point mutations of RAS have been described
in 18%–27% of poorly differentiated thyroid tumors and
in 50%–60% of ATCs (Table 2). It is likely that mutant
RAS facilitates a genomic instability predisposing to further
genetic abnormalities as those of the TP53 gene and then the
malignant progression. An example of this relation is a case
of ATC that occurred into the context of a well-differentiated
FTC where in both forms a RAS mutation has been found,
whereas a TP53 mutation has been found only in the ATC
[73].
RAS-PTC-FTC Genotype/Phenotype Correlation
PTC. The mutation of RAS in PTCs is most frequently
associated with the follicular variant of PTC, then to well-
capsulated tumors with low rates of nodal metastases [74,
75], although some studies have found a correlation between
RAS mutation and PTC with a more aggressive behavior as
the presence of distant metastases [76].
FTC. In several studies, the association between RAS muta-
tion and FTCs with a more aggressive behavior, presence
of bone metastases, has been demonstrated. These findings
support that RAS mutation can be associated with a less
favorable prognosis of FTCs [70, 77–79].
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In vitro studies showed that the mutant RAS protein
could promote a chromosomal instability and then a con-
sequent more aggressive behavior of the tumor [80, 81].
RET Gene. The RET proto-oncogene (OMIM #164761)
encodes a membrane receptor with a tyrosine kinase activity.
This receptor has an extracellular domain, containing the
signal peptide, the cadherin-like region and the cysteine-
rich region, a single transmembrane domain, and an intra-
cellular portion containing the tyrosine kinase domain [82].
The physiological ligands of RET belong to the glial-derived
neurotrophic factors (GDNFs) family, composted by four
members: neurturin, persephin, artemin, and GDNF, having
a specific trophic effect on RET [83]. The formation of
the ligand-coreceptor-receptor complex is responsible for
both the activation of the kinase catalytic domain and
the signal transduction which induces cells proliferation
through a complex network of second messengers [84]. The
tyrosine kinases are enzymes that stimulate other regulatory
proteins through phosphorylation of their tyrosine residues
and their subsequent activation stimulates the cell division
[84].
As other members of this family, RET exhibits an onco-
genic potential and plays a particularly important role in
thyroid human cancers.
Activating chromosomal rearrangements of RET are
involved in the tumorigenesis of some forms of PTC, and
its activating point mutations account for both familial and
sporadic MTC forms. In fact the 40% of PTCs are associated
with somatic gene rearrangements [85].
The familial MTC is the most important clinical feature
occurring within the Multiple Endocrine Neoplasia type 2
(MEN2) syndrome (OMIM #171400) [86].
MEN2 is an autosomal dominant disease described in
hundreds of families throughout the World. Three distinct
clinical variants of MEN2 have been reported: MEN2A,
accounting for >80% of MEN2, MEN2B, and Familial
Medullary Thyroid Carcinoma (FMTC). All variants of
MEN2 show a high penetrance for MTC; in fact, 90% of
MEN2 adult RET mutant gene carriers will eventually show
evidence of MTC [87].
MEN2-associated RET germline mutations are mostly
located in the cysteine-rich extracellular domain, particularly
in MEN2A where they are present in 90% of cases [88–
90], whereas in MEN 2B, RET germline mutation is pre-
dominantly at codon 918 in the intracellular tyrosine kinase
domain of the protein (Table 3).
Interestingly, between 1% and 24% of individuals with
MTC may have simple disease-causing germline mutations
of RET gene [91–93] and for this reason many experts
recommend DNA testing for RET in all patients with MTC
[94].
Somatic mutations of the RET gene are present in 20%–
80% of cases of sporadic MTCs [95, 96]. The vast majority
of these mutations affect codon 918, although they have
also been identified in a few other regions of the gene.
Some of these somatic mutations have an heterogeneous
distribution within the tumor or are detected only in a subset
of metastatic nodules, thereby raising concerns that they may
not be essential for carcinogenesis [95].
RET-MTC Genotype/Phenotype Correlation. The reported
strong correlation between genotype and clinical expression
of MEN2-associated MTC have provided the opportunity
to stratify three RET codon mutation categories of mutant
carrier children [87] (Table 3).
Children with MEN2B and/or RET codon 883, 918, or
922 mutations are classified as having the highest risk from
aggressive MTC and should be operated on within the first 6
months (Table 3).
Children with any RET codon 611, 618, 620, or 634
mutations are classified as intermediate level and should have
thyroidectomy performed before the age of 5 years (Table 3).
Children with RET codon 609, 768, 790, 791, 804, and
891 mutations are classified as lower-risk level and may be
operated on at a later stage (Table 3). For all groups, a more
aggressive neck dissection should be performed if evidence
of involved lymph nodes in the lateral neck [87] is found.
Patients with 791 mutation exhibit a lower penetrance
concerning MTC o C-cell hyperplasia (CCH), suggesting that
the neck surgery could be postponed up to the moment in
which we assist to the increase of simulated calcitonin serum
levels, underlying that some patients with this mutation will
never undergo prophylactic surgery [97].
Similar findings have been obtained in patients with
649L (transmembrane domain) RET mutation. It has been
reported that either patients carrying this mutation devel-
oped a mild MTC phenotype, thus delaying its diagnosis
at an older age and confirming data already reported in
literature [98, 99], or double RET mutants, 649L and 634,
exhibited a more aggressive course, with the clinical phe-
notype dominated by the “more severe” mutation, C634
[96, 100, 101].
Prophylactic thyroidectomy in 649L mutant carriers
should be correlated to the levels of stimulated calcitonin
[101].
NTRK1 Gene. NTRK1 (OMIM #155240) tyrosine kinase
gene is located on chromosome 1q22 and encodes for
the receptor for nerve growth factor (NGF) (Table 2). Its
oncogenic activation occurs through a chromosomal rear-
rangement [102]. NTRK1 rearrangements are less frequent
than reported for RET [103].
PI3K/AKT Pathway and PTEN Gene Mutations. Protein
RAS and fusion protein RET/PTC may activate the PI3K/
AKT (phosphatidylinositol 3-kinase/Akt) signaling pathway
through the loss of function of PTEN [104].
PI3K are a family of related intracellular signal transducer
enzymes capable of phosphorylating the inositol ring of
phosphatidylinositol. AKT protein family, whose members
are also called protein kinases B (PKB), plays an important
role in mammalian cellular signaling.
PTEN is a protein that, following activating mutations
or amplifications of the genes encoding the effector pro-
teins of PI3K/AKT pathway, inhibits PI3K signaling. Since
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the PI3K/AKT pathway is fundamental in regulating cell
growth, proliferation, and survival, mutations of the PIK3CA
gene (OMIM #114480), encoding the catalytic subunit of
PI3K, have been searched in thyroid tumors and found in
6%–13% of FTCs and in 0%–6% of follicular adenomas
[105–107].
As mentioned above, mutations of PTEN gene (OMIM
#601728), involved in thyroid carcinogenesis, are responsible
for CD which is characterized by the occurrence of hamar-
tomas in multiple organs, benign thyroid lesions such as
multinodular goiter and thyroid adenoma and exhibit an
increased risk of thyroid cancer (especially FTC) and breast
[33].
PTEN and FTC. Mutations of PTEN gene have been
reported in about 7% of FTCs, whereas they have not been
found in follicular adenomas [106, 107] (Table 2).
PTEN and ATC. Point mutations of PIK3CA and PTEN
genes have been reported in approximately 20% and 15% of
ATCs cases, respectively [105, 106, 108] (Table 2).
TP53 Gene. TP53 gene (OMIM #191170) encodes a protein
that is essential to maintain the integrity of the genetic
heritage, as it protects the body against genetic damage
that induces cancer by stimulating the production of both
proteins that inhibit proliferation and promote cell differen-
tiation, either DNA repair or apoptosis.
Inactivating point mutations of TP53 make the encoded
protein unable to enter the nucleus, so it cannot longer
control the production of regulating proteins, and, therefore,
the above mentioned events. This has been demonstrated by
studies in which the recovery of the expression of TP53 in
ATCs cultured cells would reduce the rate of proliferation,
the reexpression of thyroid-specific genes (e.g., TPO, PAX-8),
regaining the ability to respond to stimulation with thyroid
hormone [109, 110].
Mutations of TP53 represent the most common genetic
alterations of all types of human cancers.
In the thyroid these mutations are present in approxi-
mately 60%–80% of ATCs, in 30% of poorly differentiated
tumors, and only rarely in FTCs and PTCs (Table 2), mostly
involving the exons 5–8 of the gene [111–115].
CTNNB1 (β-Catenin) Gene. CTNNB 1 gene (OMIM
#116806) encodes β-catenin, a cytoplasmic protein which is
an important intermediary in the wingless signaling pathway
(WNT) [116, 117]. The Wnt signaling pathway consists
of a complex network of proteins playing important roles
in embryogenesis and cancer, and also involved in normal
physiological processes in adult animals [118].
Point mutations at exon 3 of CTNNB1 gene have been
found in 25% of poorly differentiated carcinomas and 66% of
ATCs, respectively, but not in well-differentiated carcinoma
[119, 120] (Table 2).
Mitochondrial DNA: Gene Mutations. Somatic point muta-
tions and deletions of mitochondrial DNA have been
found to be more frequent in adenomas and oncocytic
carcinomas, whereas they are more rare in PTCs and FTCs
[121].
Recently, in 15% of oncocytic tumors, but not in other
types of TC, mutations in the GRIM-19 gene (OMIM
609435), encoding for a protein involved in the process of cell
death and mitochondrial metabolism, have been identified,
suggesting that the alteration of GRIM-19 gene may serve as
a specific marker of such tumors [121, 122].
9.2.2. Gross Mechanisms: Gene Rearrangements and
Loss of Heterozygosity
Gene/Chromosomal Rearrangements
RET/PTC Genes. In 40 % of PTCs, RET/PTC rearrangement
has been described [85] (Table 2). The rearrangement
involved the fusion between the portion 3′ of the gene for
the receptor tyrosine kinase RET and the portion 5′ of het-
erologous genes [85]. RET/PTC1, RET/PTC3, and RET/PTC2
are the most frequent types of the rearrangement found in
PTCs.
RET/PTC1 and RET/PTC3 are paracentric inversions
because RET and H4 (OMIM #601985) or NCOA4 (ELE1)
(OMIM 601984), the respective fusion partners, both reside
on chromosome 10q where RET is located [123, 124].
Specifically, the abnormal fusion protein RET/PTC1(H4-
RET) is a constitutively activated tyrosine kinase, whereas
NCOA4 (Nuclear receptor coactivator 4) gene encodes an
androgen receptor coactivator.
On the contrary, RET/PTC2 is due to an interchromo-
somal translocation between chromosome 10 and chromo-
some 17 [125].
Other types of RET/PTC rearrangements have been
subsequently identified. Most of these rare types of RET/PTC
have been found in 50%–80% of PTCs in patients with a
history of previous environmental (such as the Chernobyl
nuclear accident) or therapeutic exposure to ionizing radi-
ation and in 40%–70% of PTCs of children and young adults
[126–130].
Rearrangements such as RET/ELKS (OMIM #607127),
t (10;12) (q11;p13), and RET/HOOK3 (OMIM ∗607825;
Homo sapiens hook homolog 3) have also been seen in
patients with sporadic PTC [131, 132].
In particular, ELKS gene localizes onto chromosome
12p13.3 and its amino acidic sequence is rich in glutamic acid
(E), leucine (L), lysine (K), and serine (S).
All the fusion events leave the domain of the receptor
tyrosine kinase RET intact and allow RET/PTC oncoprotein
to bind SHC (OMIM #600560), involved in RAS regulation
[133]; SHC (Src homology 2 domain containing) trans-
forming protein 1, also known as SHC1, is a human gene
[134].
In approximately 20% of sporadic PTCs RET/PTC
rearrangements have been found [135, 136]. RET/PTC
rearrangement is regarded as an early event in thyroid
carcinogenesis and it is frequently found in papillary
microcarcinoma [137]. Moreover, it has been also found in
adenomas and other benign lesions of the thyroid. However,
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since it is present in most tumor cells, it is reasonable to
consider it specific for PTCs [138–140].
PAX8 /PPARγ Genes. PAX8/PPARγ rearrangement, due to
the fusion of the PAX8 (OMIM #167415) gene with the
PPARy gene (OMIM #601487), results from t(2;3) (q13,p25)
translocation [141]. PAX8 gene is a member of the paired
box (PAX) family of transcription factors whereas PPARγ
gene encodes for nuclear receptor protein which functions
as transcription factor regulating the expression of several
genes.
PAX8/PPARγ rearrangement has been found in 35%
FTCs, in 2%–10% of follicular adenomas, and at a lower
percentage in the Hurtle’s cell carcinoma [142–144] (Table 2)
suggesting these injuries to be preinvasive (in situ) forms of
FTCs.
Tumors expressing such a rearrangement occur at a
young age and are small in size with a solid growth
pattern or nests and vascular invasion. The mechanisms of
cell transformation induced by PAX8/PPARγ are not fully
known [143–145]. Immunohistochemical techniques allow
us to detect that the rearrangement consists of an over-
expression of the PPARγ protein although only an intense
and diffuse nuclear staining correlates with the presence of
the rearrangement [141, 146].
Several studies have been conducted on this rearrange-
ment, and various mechanisms have been observed and
assumed to have a possible role on (1) inhibition of the
normal function of PPARγ by a dominant negative effect
on the mutant protein PAX8/PPARγ on PPARγ wild type
[141, 147], (2) activation of PPARγ target genes in tumors
expressing PAX8/PPARγ, (3) deregulation of PAX8 function,
known to be crucial for the differentiation of thyroid cells,
and (4) activation of genes not related either to the wild-type
PPARγ or to the PAX8 pathways [148, 149].
LOH Studies. Another genetic alteration, a gross alteration,
reported in the TCs is LOH.
LOH represents the loss of the normal function of
one allele of a gene in which the other allele was already
inactivated at somatic or germline level.
LOH is detected on average in 6%–12% of follicular
adenomas and in 30%–50% of FTCs.
The chromosomal regions most frequently involved are
located on chromosomes 2p, 3p, 9q, 9p, 10q, 11p, 17p, and
15q [150–152].
LOH Genotype/Phenotype Correlation. The frequency of
LOH has been correlated with the aggressiveness of the
tumor and the presence of relapse in patients with FTC. In
fact, in the minimally invasive tumors LOH has been detected
in 30% of cases, while its frequency was greater in 50% of
more aggressive cases and in the presence of disease relapse
[151, 153].
A study conducted on a small group of FTCs has
suggested that allelic loss of the VHL gene on 3p26 may
serve as important diagnostic and prognostic markers of
FTCs being specific for malignancy, even though its clinical
usefulness should be validated in a larger group of tumors
[154–157].
LOH is more present in thyroid oncocytic tumors. The
most affected regions resulted to be located on chromosomes
1q, 2p, 3q, 8q, 14q, and 18q [154, 156], but also the loci on
chromosome 1q and 2p showed a significantly higher rate
of LOH in oncocytic carcinomas than in adenomas, with a
sensitivity of 100% and a specificity of 65% for the detection
of malignant tumors [156].
9.2.3. MicroRNAs (miRNAs). miRNAs are a class of small
noncoding RNAs involved in a wide range of processes
such as proliferation, development, apoptosis, metabolism,
and response to stress. In studies conducted in different
types of human tumors, it has been shown that miRNAs
are abnormally expressed [158]. miRNAs profile expression
analysis in human TCs, by microarray approach, detected an
aberrant expression of several miRNAs in PTCs [159].
Overexpression of mir-221, -222, and-181b has been also
demonstrated in transformed rat thyroid cell lines and in
mouse models of thyroid carcinogenesis.
Functional studies, performed by blocking mir-221 func-
tion and by overexpressing mir-221 in human PTC-derived
cell lines, have suggested a critical role of mir-221 overex-
pression in thyroid carcinogenesis. Taken together, these data
have indicated the existence of an miRNA signature associ-
ated with PTCs, and suggested the miRNA deregulation as
an important event in thyroid cell transformation [160].
Overexpression of mir-221 in PTC may drive gene
expression patterns by directly and indirectly regulating
numerous genes, including HOXB5 [161, 162]. HOXB5 gene
encodes a nuclear protein with a homeobox DNA-binding
domain and the encoded protein functions as a sequence-
specific transcription factor that is involved in several tissue
developments [163].
Molecular Therapy. In oncology, understanding of the
molecular mechanisms that control cell growth and survival
has led to the development of new more selective and
targeted pharmacological agents.
Compounds that have demonstrated a potential pre-
clinical therapeutic application in TC are discussed below.
Inhibitors of BRAF Protein. Since alterations of BRAF are
widely represented in many solid tumors, such as malignant
melanoma, it is clearly appreciated the considerable interest
directed to the development of specific inhibitors of BRAF
activity [45, 53]. Among these, the best known is the bi-
aryl urea BAY 43-9006 (sorafenib) [164]. BAY 43-9006
is an inhibitor active against RAF multikinase and other
proteinkinase (VEGFR-2 and PDGFR), which can effectively
block the kinase activity of BRAF [46, 165]. Preclinical
studies have demonstrated its ability to inhibit the BRAF
signal and growth of all of the thyroid carcinoma cell lines
expressing this oncogene [166]. BAY 43-9006 has been tested
on several types of human carcinomas including TCa, and
the preliminary results showed a minimal or partial response
in some patients [167].
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Currently, numerous other compounds are being stud-
ied. They include AAL881 and LBT613, which has not
demonstrated in vitro an efficacy exceeding that of sorafenib
[168].
Inhibitors of RET. The somatic rearrangements of the
RET proto-oncogene, in particular those resulting from
rearrangements RET/PTC, form various oncoproteins that
represent potential molecular targets for the development of
specific inhibitors. Indeed, several studies have demonstrated
their high frequency in PTCs and their ability to intervene
early in the process of neoplastic transformation [169].
Several inhibitors of the enzyme activity of RET have
been developed, some of natural origin such as herbimicine
A, clavilactones, and other synthetics [170, 171]. Their
mechanism of action interferes with the ATP-binding site at
the catalytic domain of RET molecule. The most effective
compounds belong to the class of indolocarbazoles (CEP-
701, CEP 751) [172], pyrazolopyrimidine (PP1, PP2) [173,
174], quinazoline (ZD6474) [175, 176], and indolinones
(RPI-1) [177–179].
These compounds, in addition to directly inhibit the
activity of RET, can also act on other downstream kinases
involved by activated RET as the inhibition of Fak from PP2
[174].
ZD6474 is a tyrosinkinase inhibitor, belonging to the
family of quinazoline, blocking effectively RET and the type
2 receptor of VEGF [175, 180]. In an in vitro study ZD6474
also stops the growth of human PTC cell lines expressing
RET/PTC1 and prevents the growth of fibroblasts in mice
expressing RET/PTC3 [181, 182].
As mentioned above, BAY 43-9006 binds to RAF-1,
BRAF, and other receptor tyrosine kinases responsible for
neoangiogenesis and tumor progression (VEGFR-2, VEGFR-
3, FLT-3, PDGFR-B, and KIT). Moreover, BAY 43-9006 also
seems to be able to inhibit the activity of RET and the
tumoral growth [183].
Multikinase inhibitor, SU12248 (sunitinib), has proven
to be effective in inhibiting the RET/PTC kinase signal in
experimental models and it has been tested in a phase II study
on differentiated TC, refractory to radiometabolic therapy
and not surgically resectable [184].
EEE 788 (cetuximab) has been shown to have antiangio-
genetic effects by blocking EGF-R and VEGF-R in cell lines
of TC [185].
AMG706 is another multikinase inhibitor with anti-
cancer and antiangiogenetic effects, directed selectively
against VEGF receptors (VEGFR1, VEGFR2, VEGFR3),
PDGF, Kit, and RET [186]. In a recent phase 1 clinical
study on a small group of patients with different histotypes
of TC, AMG706 seems to be well tolerated and potentially
reduces either the volume of the tumor or cancer biochemical
markers [187].
Practical Applications of Molecular Genetics to the Clinical
Approach for TCs. In recent years, multiple genetic alter-
ations have been identified in differentiated TC, leading
to test the clinical utility of genetic studies. In particular,
molecular genetic approaches searching for gene mutations
in the material collected by FNAB may have a particular
utility in small nodules and in those specimen with an
indeterminate cytology.
Considering that FNA presents a false-negative rate of
1% to 11%, a false-positive rate of 1% to 8%, a sensitivity of
65% to 98%, and a specificity of 72% to 100%, its limitations
are related to the skill of the operator, the expertise of the
cytologist, and the difficulty in distinguishing some benign
cellular adenomas from their malignant counterparts [188].
BRAF Mutations. The detection of somatic BRAF mutations
provided the diagnosis of PTC in 15%–30% of cases with
doubtful cytology [189, 190]. The search for somatic BRAF
mutations, performed on specimen obtained by FNAB, not
only may allow a preoperative diagnosis, but also it is easy to
be performed on small amounts of DNA and not particularly
expensive since it is mainly restricted to a single mutation
[191–193]. Importantly, detection of BRAF V600E mutation
can be successfully achieved by various molecular techniques
using DNA isolated from fresh or fixed FNAB samples. Four
different detection methods revealed a comparable and high
sensitivity of the detection in archival FNAB smears [194].
RAS Mutations. The diagnostic value of searching for
somatic RAS mutations is still controversial because it is
not a specific indicator of malignancy, being also present
in benign follicular adenomas. However, RAS mutations
arise frequently in FTC and follicular variant of PTC, both
histotypes difficult to diagnose at cytology performed by
FNAB. Considering the key role played by mutant RAS, both
in the progression of MTC and undifferentiating cancer, it
has been recommended the surgical removal of RAS-positive
adenomas in order to avoid the potential transformation into
malignant forms [195].
In a prospective study aimed to analyze the role of the
search for different mutations in improving the preoperative
diagnosis of thyroid nodules by FNAB, the identification of
RAS mutations has been found effective in ameliorating the
diagnostic accuracy and allowing the diagnosis of malignant
tumors in many samples with a previous negative or
inadequate cytological diagnosis [196].
RET/PTC Genes Rearrangements. The RET/PTC rearrange-
ments may be sought for diagnostic purposes in the samples
obtained by cytology performed with FNAB for a better
definition of the preoperative diagnosis of thyroid nodules,
especially in samples with indeterminate cytology or having
an insufficient quantity of cells for a diagnostic purpose
[140, 190, 197, 198].
Searching for BRAFMutations and RET/PTC Rearrangements:
A Comparison among the Specificities. When compared to
the search for BRAF mutations, the molecular approach
for RET/PTC rearrangements detection needs a more deep
investigation since it requires the extraction of RNA and the
search for at least two rearrangements of RET (RET/PTC1
and RET/PTC3).
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The specificity is lower because, unlike the BRAF muta-
tions present only in PTCs, RET/PTC rearrangements may
also be found in benign thyroid diseases (sporadic follicular
adenomas, benign thyroid nodules, and Hashimoto’s thy-
roiditis) [137, 139, 199–201].
PAX8/PPARγ Genes Rearrangements. The analysis for the
PAX8/PPARy rearrangement may be useful in diagnosis, even
if it has to be taken into account that this genetic alteration is
not unique to the FTC, but it can also be found in follicular
adenoma and PTC.
The identification of the PAX8/PPARy rearrangement
needs sophisticated and expensive methods such as RT-PCR
(reverse transcription-polymerase chain reaction), which
is a highly sensitive technique for mRNA detection and
quantitation [202], FISH (fluorescence in situ hybridization)
[203], or immunohistochemistry.
It has been suggested that the detection of an intense
and diffuse immunoreactivity of PPARγ in tumor cells may
justify the analysis of new sections of the tumor capsule and a
more accurate appraisal of the suspicious areas in the search
of capsular and/or vascular invasion [204].
10. Conclusions
TC is one of the most important malignant tumors of
the endocrine system. Its incidence is increasing over the
years, approximately 1% of all the new diagnoses of cancer.
Its etiology appears to be multifactorial, being due to the
interaction between environmental factors, among which the
most important are exposure to radiation and the lack of
iodine in the diet, and genetic factors. The expansion of
knowledge about genetic mutations occurring in different
thyroid tumors has characterized recent years, allowing the
identification of a correlation between specific mutations
and phenotypic characteristics of thyroid cancers, essential
for their prognosis. First example is represented by BRAF
mutation that appears to be an indicator of an aggressive
behavior of PTC. Studies of this mutation were later extended
to the development of new targeted therapies for TC such
as the ones represented by inhibitors of RET- and BRAF-
dependent tyrosine kinase activity, as also other molecular
targets, currently under development or already in stages
of clinical trial. The results of these trials should provide
us with the therapeutic efficacy of these treatments and
their potential use, whether developed as monotherapy or as
associations of multiple drugs, especially in the treatment of
aggressive thyroid tumors such as medullary carcinoma, the
poorly differentiated cancer, and anaplastic carcinoma.
The application of genetic research of particular muta-
tions to the diagnosis has allowed to improve the cytological
diagnosis in those samples with FNA cytology indeterminate
and/or atypical. The identification of BRAF mutation is
particularly promising since the simple realization and the
high specificity of the analysis for the determination of
malignancy.
However, despite the analysis of all of the several known
mutations, up to now the molecular test alone is not
sufficient to detect all cases of malignancy. In fact, in various
percentages in both the PTC and FTC and especially in
oncocytic carcinomas, these mutations do not reach a high
degree of specificity.
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